Taken together, the known roles of TP53, PLCG1, SYK, and SOD1 and their interactions with multiple PPI networks of gene expression markers suggested their roles in the mediating distinct cell response to TKI treatment of CML. Here, PLCG1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.